Ignite Creation Date:
2024-05-05 @ 11:23 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00019461
Status:
COMPLETED
Last Update Posted:
2013-06-20
First Post:
2001-07-11
Brief Title:
Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial Fallopian Tube or Primary Peritoneal Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase II Trial of Orally Administered CAI for Patients With Persistent or Refractory Epithelial Ovarian Cancer Fallopian Tube Cancer or Primary Peritoneal Cancer
Status:
COMPLETED
Status Verified Date:
2003-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE Phase II trial to study the effectiveness of carboxyamidotriazole in treating patients with refractory or recurrent ovarian epithelial fallopian tube or primary peritoneal cancer
PURPOSE Phase II trial to study the effectiveness of carboxyamidotriazole in treating patients with refractory or recurrent ovarian epithelial fallopian tube or primary peritoneal cancer
Detailed Description:
OBJECTIVES
Determine the clinical outcome in patients with ovarian epithelial fallopian tube or primary peritoneal cancer treated with carboxyamidotriazole
OUTLINE Patients receive oral carboxyamidotriazole daily beginning on day 1 Treatment continues in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A total of 19-40 patients will be accrued for this study within 2 years
Determine the clinical outcome in patients with ovarian epithelial fallopian tube or primary peritoneal cancer treated with carboxyamidotriazole
OUTLINE Patients receive oral carboxyamidotriazole daily beginning on day 1 Treatment continues in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A total of 19-40 patients will be accrued for this study within 2 years
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-T97-0112 | None | None | None |
| NCI-98-C-0012 | None | None | None |